Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Topas Therapeutics GmbH holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action in the portfolio. This action is being handled by 1 distinct examiner and is located in 1 distinct art unit, indicating a concentrated prosecution focus.
The busiest examiner for the company is STEINKE, SEAN JAMES, who is responsible for 1 pending office action. With only 1 pending office action total, this examiner manages the entirety of the company's current pending workload. The focus on 1 distinct art unit indicates that the company's current biotechnology prosecution is concentrated in a single specialized area of the patent office. For a practitioner, this means the success of the company's current biotechnology filings depends entirely on the outcome of this single office action with STEINKE, SEAN JAMES. The presence of 1 distinct examiner for the only pending action in the portfolio highlights a singular point of focus for the company's current biotechnology prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEINKE, SEAN JAMES | 2 | 12.5% | +42.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17904311 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | STEINKE, SEAN JAMES | 5d |
| 18684452 | Pharmaceutical Composition Comprising Nanoparticles for the Targeted Delivery of Antigens | STEINKE, SEAN JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17904311 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | STEINKE, SEAN JAMES | 5d |
| 18684452 | Pharmaceutical Composition Comprising Nanoparticles for the Targeted Delivery of Antigens | STEINKE, SEAN JAMES | — |
| Art Unit | Apps |
|---|---|
| 1619 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684452 | Pharmaceutical Composition Comprising Nanoparticles for the Targeted Delivery of Antigens | STEINKE, SEAN JAMES | 1619 | §103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 17904311 | AMPHIPHILIC POLYMERS AND THEIR USE FOR IMPROVED PRODUCTION OF NANOPARTICLES FOR THE TARGETED DELIVERY OF ANTIGENS | STEINKE, SEAN JAMES | 1619 | §102§103Other | Final Rejection | 5d | Pending | Aug 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial